Central Nervous System-Anticonvulsants
= Additional active ingredients
PRESENTATION AND DOSSAGE
TABS: 60 X 250 mg
TABS: 60 X 500 mg
TABS: 60 X 1000 mg
IV VIAL: 10 X 29G
For adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy.As adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. As monotherapy in the treatment of partial onset seizures with or without secondary generalization in patients from 16 years of age with newly diagnosed epilepsy. Treatment of primary generalized tonic-clonic seizures (PGTCS) in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Hypersensitivty to levetiracetam or other pyrrolidone derivatives or any of the excipients.
If discontinued, withdraw gradually (e.g. 500 mg 2 x daily decrements every 2-4 weeks.) Administration to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection.
Pregnancy and lactation: Should not be used during pregnancy unless clearly necessary. Discontinuation of antiepileptic treatments may result in worsening of disease, harmful to the mother and fetus. Breast-feeding is not recommended. Caution is recommended when performing skilled tasks, e.g. driving vehicles and operating machinery.
Very common: Asthenia, somnolence. Common: Amnesia, ataxia, convulsion, dizziness, headache, tremor. Depression, emotional lability, hostility, insomnia, nervousness. Diarrhea, dyspepsia, nausea, anorexia, vertigo. Diplopia, accidental injury, rash.
MANUFACTURER & DISTRIBUTER:
Manufacturer: UCB S.A., Belgium
License Holder: CTS Chemical Ind. Ltd.